Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01391130 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT01391130 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 110 participants.
The verdict
NCT01391130, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
To compare the progression free survival of LY2510924 plus sunitinib therapy versus sunitinib in the first-line setting for patients with metastatic clear-cell renal cell carcinoma.
Interventions
- DRUG Sunitinib
- DRUG LY2510924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2011-08 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01391130
The ClinicalTrials.gov registry entry for NCT01391130 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sunitinib is the first listed.
NCT01391130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01391130 about?
NCT01391130 is a clinical study titled "A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma". To compare the progression free survival of LY2510924 plus sunitinib therapy versus sunitinib in the first-line setting for patients with metastatic clear-cell renal cell carcinoma.
What is the current status of trial NCT01391130?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2011-08. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01391130?
The interventions under investigation include: Sunitinib (DRUG), LY2510924 (DRUG).
Who is sponsoring clinical trial NCT01391130?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.